NLRP3 and diabetic kidney disease: Differently, astragaloside IV protects podocytes from diabetic nephropathy by modulating the NLRP3 inflammasome (Hu Z. et al., 2024), a mechanism that parallels the action of ginsenosides Rg1, Rg2, and Rg5 (Wang T. et al., 2020; Zhu et al., 2020; Li K. et al., 2025).